| Safety, Tolerability, and Pharmacokinetics of HL-003 in Healthy Subjects (NCT06867393) | Shanghai Kechow Pharma, Inc. | 2025-02-28 |
| Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma (NCT06008106) | Shanghai Kechow Pharma, Inc. | 2023-11-02 |
| Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (NCT06008119) | Shanghai Kechow Pharma, Inc. | 2023-10-25 |
| Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study (NCT05900219) | Shanghai Kechow Pharma, Inc. | 2023-09-24 |
| Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC) (NCT05233332) | Shanghai Kechow Pharma, Inc. | 2022-02-24 |
| HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (NCT05331105) | Shanghai Kechow Pharma, Inc. | 2021-10-18 |
| HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation (NCT05263453) | Shanghai Kechow Pharma, Inc. | 2021-09-06 |
| HL-085 in NRAS-mutated Advanced Melanoma (NCT05217303) | Shanghai Kechow Pharma, Inc. | 2020-11-02 |
| Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC (NCT03990077) | Shanghai Kechow Pharma, Inc. | 2020-05-21 |
| Phase I Study of HL-085 in Patients With Advanced Solid Tumors (NCT03976050) | Shanghai Kechow Pharma, Inc. | 2019-06-17 |
| A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation (NCT03781219) | Shanghai Kechow Pharma, Inc. | 2018-07-01 |
| Study of HL-085 in NRAS Mutant Advanced Melanoma (NCT03973151) | Shanghai Kechow Pharma, Inc. | 2017-09-01 |